Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open, uncontrolled phase II trial to verify the efficacy and safety of combination with cisplatin / docetaxel and cetuximab in patients with locally advanced or metastatic adenocarcinoma of the stomach or gastroösophagalen transition. [Offene, unkontrollierte Phase II-Studie zur Überprüfung der Wirksamkeit und Verträglichkeit einer Kombination mit Cisplatin/Docetaxel und Cetuximab bei Patienten mit lokal fortgeschrittenem oder metastasiertem Adenokarzinom des Magens oder gastroösophagalen Übergangs.]

Next Previous
Trial Profile

Open, uncontrolled phase II trial to verify the efficacy and safety of combination with cisplatin / docetaxel and cetuximab in patients with locally advanced or metastatic adenocarcinoma of the stomach or gastroösophagalen transition. [Offene, unkontrollierte Phase II-Studie zur Überprüfung der Wirksamkeit und Verträglichkeit einer Kombination mit Cisplatin/Docetaxel und Cetuximab bei Patienten mit lokal fortgeschrittenem oder metastasiertem Adenokarzinom des Magens oder gastroösophagalen Übergangs.]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Sep 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top